This trial is a prospective, randomized clinical trial in patients undergoing ablation for symptomatic persistent AF to assess whether adding OPTIMA ablation to PVI improves freedom from AF.
- Chronic Atrial Fibrillation
1 Primary · 3 Secondary · Reporting Duration: 1 year
2 Treatment Groups
Standard Ablation (PVI)
1 of 2
1 of 2
200 Total Participants · 2 Treatment Groups
Primary Treatment: OPTIMA Ablation · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
To what extent is the sample size being utilized in this medical study?
"Indeed, clinicaltrials.gov displays that this study is currently enrolling volunteers. This trial was published on September 1st 2019 and has been revised as recently as 9/26/2022. 200 individuals across one medical site are required to fulfill the enrolment goals of this research project." - Anonymous Online Contributor
Are there any openings for participants in this trial currently?
"According to clinicaltrials.gov, this trial is in need of participants and has been since September 1st 2019. The study was most recently updated on the 26th of September 2022." - Anonymous Online Contributor